Sitagliptin Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Alone In a 24-week placebo-controlled trial of sitagliptin 100 mg administered once daily added to a twice daily metformin regimen, there were no adverse reactions reported regardless of investigator assessment of causality in 5% of patients and more commonly than in patients given placebo
Novo Nordisk, the company that funded the most recent study, makes both Wegovy and Ozempic, the two most popular drugs that have semaglutide as the active ingredient
Both are classified as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and have shown promising results in aiding weight management in patients with obesity and related comorbidities
In the 68-week Phase 3 STEP TEENS trial, weekly semaglutide (2.4 mg) plus lifestyle produced a mean 16.1% change in BMI from baseline vs
Waters Corporation) using an ACQUITY UPLC system (Waters Corporation)
These products are not drugs, foods, or cosmetics, and are not intended to diagnose, treat, cure, or prevent any disease
